Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keytruda +/- Copanlisib in R/R NK/T-cell Lymphoma
NCT02535247Phase 2Terminated
- Sponsor
- Fox Chase Cancer Center
- Start
- Jan 2016
- Primary completion
- Feb 2020
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in natural killer cell lymphoma (NKCL), peripheral T-cell lymphoma (PTCL), sponsored by Fox Chase Cancer Center. Started Jan 2016; status: terminated.
02
Drugs
03
Conditions
natural killer cell lymphoma (NKCL)peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT02535247.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02535247.